Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Jun 16;6(8):e1338236. doi: 10.1080/2162402X.2017.1338236

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2017 The Author(s). Published with license by Taylor & Francis Group, LLC

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.

PMC Copyright notice

Figure 6. — T cells originated from adoptively transferred splenocytes of donors cured by LTX-315 and inhibit the development of rTMSCs in naïve recipients. (A) Recipient rats were conditioned with total body irradiation (TBI) of 600 cGy one day before adoptive spleen cell transfer. Surviving rats were rechallenged twice after the initial LTX-315 treatment was used as a splenocyte donor. A group of rats (n = 15) received isolated spleen cells (30·10⁶) from cured rats. Another group of rats (n = 6) were given T-cell depleted (TCD) splenocytes (18·10⁶) from cured donors, whereas spleen cells (30·10⁶) from naïve rats were transferred to rats in the control group (n = 5). One day after splenocyte transfer, animals were s.c. inoculated with 1·10⁴ rTMSCs. The measurement of tumor development was tracked by bioluminescence imaging. (B) Representative images of recipient rats receiving spleen cells from cured donors (LTX-315), or from naïve donors (control) at designated days after tumor challenge. (C) Survival curve comparing tumor-free survival in animals receiving splenocytes from cured donors (solid line), TCD fraction of splenocytes (dashed line) or splenocytes from naïve donors (dotted line).